Our services

ADC Review
is made possible by:




Ado-trastuzumab Emtansine (Kadcyla®) Drug Description

Ado-trastuzumab emtansine also know as T-DM1 (Kadcyla®; Genentech/Roche) is a human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that comprises the humanized anti-HER2 IgG1 (antibody) trastuzumab linked to the anti-mitotic agent mertansine (a maytansine derivative; also known as the maytansinoid DM1).

The antibody-drug conjugate combines two strategies: the anti-HER2 activity of trastuzumab, and the targeted intracellular delivery of mertansine, a tubulin polymerisation inhibitor which interferes with mitosis and promotes apoptosis.

The linker in trastuzumab emtansine is a non-reducible thioether linker, N-succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC, designated MCC after conjugation). Emtansine refers to the MCC-DM1 complex.

Trastuzumab is a well characterized recombinant monoclonal antibody produced by mammalian (Chinese Hamster Ovary/CHO) cells. The small molecule cytotoxin, DM1, a microtubule inhibitor,  and MCC linker are produced by chemical synthesis. Ado-trastuzumab emtansine contains an average drug-to-antibody ratio (DAR) of 3.5 DM1 molecules per antibody. [1]

Ado-trastuzumab emtansine
Figure 1.0. Ado-trastuzumab emtansine. Source: Highlights of Prescribing Information (USA); ado-trastuzumab emtansine (T-DM1; Kadcyla®/Genentech/Roche).

Mechanism of Action
Upon binding to sub-domain IV of the HER2 receptor, ado-trastuzumab emtansine undergoes receptor-mediated internalization and subsequent lysosomal degradation, resulting in intracellular release of DM1-containing cytotoxic catabolites. Binding of DM1 to tubulin disrupts microtubule networks in the cell, which results in cell cycle arrest and apoptotic cell death.[1]

The cytotoxic effect of ado-trastuzumab emtansine varies depending on the intracellular concentration of DM1 accumulated in cancer cells, high intracellular levels resulting in rapid apoptosis, somewhat lower levels in impaired cellular trafficking and mitotic catastrophe, while the lowest levels lead to poor response to ado-trastuzumab emtansine.[2]

Binding of ado-trastuzumab emtansine to the extracellular domain of HER2 triggers entry of the antibody-drug conjugate complex into cancer cells via receptor-mediated endocytosis [3]. A high rate of internalization may result in high intracellular concentrations of DM1, and deceleration of the endocytosis rate might cause loss of sensitivity to ado-trastuzumab emtansine. [4]

In vitro studies have shown that similar to trastuzumab, ado-trastuzumab emtansine inhibits HER2 receptor signaling, mediates antibody-dependent cell-mediated cytotoxicity and inhibits shedding of the HER2 extracellular domain in human breast cancer cells that overexpress HER2.

Approval
Ado-trastuzumab emtansine is as a single agent, second-line mono therapy,  for the treatment of patients with HER2+ metastatic breast cancer (MBC) who previously received trastuzumab and a taxane, separately or in combination. Patient’s:

  • Received prior therapy for metastatic disease, or
  • Developed disease recurrence during or within six months of completing adjuvant therapy.

Ado-trastuzumab emtansine is approved for marketing by the U.S. Food and Drug Administration (FDA) and the European Medicine Agency (EMA).

HER2+ metastatic breast cancer
Over-expression or amplification of HER2 occurs in approximately 20% of breast cancers and is associated with more aggressive tumors and poorer prognosis in the absence of treatment. Although effective therapies for the initial management of HER2-positive metastatic breast cancer (MBC) exist, many patients will experience disease progression.

Drug resistance
Despite favorable efficacy results of ado-trastuzumab emtansine, most treated patients eventually progress, and some HER2-positive breast cancers are primarily non-responsive or are only minimally responsive to ado-trastuzumab emtansine. [5]

Most second-line therapies are associated with either significant toxicities or limited improvements in overall survival (OS).

Clinical trials
In randomized clinical trials efficacy has been demonstrated as first line, second line, and later than the second line treatment of advanced breast cancer.[2]


Last Editorial Review: September 15, 2015

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Manuscript Guidelines & Tips

Skip to toolbar